Literature DB >> 890999

Amiloride in the treatment of primary hyperaldosteronism and essential hypertension.

D Kremer, K Boddy, J J Brown, D L Davies, R Fraser, A F Lever, J J Morton, J I Robertson.   

Abstract

Amiloride (40 mg/day) was given to nineteen patients with primary hyperaldosteronism. There were significant falls in systolic and diastolic blood pressure, in total exchangeable sodium, and in serum sodium sodium and bicarbonate; while total exchangeable potassium, total body potassium, serum potassium, chloride and urea, and plasma renin, angiotensin II and aldosterone all increased significantly. Amiloride was effective in reducing blood pressure in patients with and without adrenocortical adenoma. No carry-over effect was seen on withdrawing amiloride. Similar changes were associated with amiloride treatment in five patients with essential hypertension; hyperkalaemia was not observed. Only negligible side-effects were encountered in the entire series of twenty-four patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 890999     DOI: 10.1111/j.1365-2265.1977.tb01307.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

1.  Variation of phenotype in patients with glucocorticoid remediable aldosteronism.

Authors:  L J Gates; A A MacConnachie; R P Lifton; N E Haites; N Benjamin
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

Review 2.  [Modern pharmacological aspects of hyperaldosteronism therapy].

Authors:  M Quinkler; M Reincke
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

3.  Primary aldosteronism: how hard should we look?

Authors:  J D Swales
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-10

4.  Relation of plasma aldosterone concentration to diuretic treatment in patients with severe heart disease.

Authors:  R K Knight; P A Miall; L A Hawkins; J Dacombe; C R Edwards; J Hamer
Journal:  Br Heart J       Date:  1979-09

5.  ENaC inhibition stimulates Cl- secretion in the mouse cortical collecting duct through an NKCC1-dependent mechanism.

Authors:  Vladimir Pech; Monika Thumova; Young Hee Kim; Diana Agazatian; Edith Hummler; Bernard C Rossier; Alan M Weinstein; Masayoshi Nanami; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-11

6.  Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects.

Authors:  J A Millar; R Fraser; P Mason; B Leckie; A M Cumming; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

7.  Amiloride enhances the secretion but not the synthesis of renin in renal juxtaglomerular cells.

Authors:  A Kurtz; R Della Bruna; H Scholz; W Baier
Journal:  Pflugers Arch       Date:  1991-08       Impact factor: 3.657

Review 8.  Secondary hypertension. An overview of its causes and management.

Authors:  D H Streeten; G H Anderson
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

9.  Regulation of aldosterone secretion by Cav1.3.

Authors:  Catherine B Xie; Lalarukh Haris Shaikh; Sumedha Garg; Gizem Tanriver; Ada E D Teo; Junhua Zhou; Carmela Maniero; Wanfeng Zhao; Soosung Kang; Richard B Silverman; Elena A B Azizan; Morris J Brown
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.